EPO and chronic kidney disease: Initial studies showed that in anemic patients with chronic kidney disease on dialysis, EPO treatment was administered three times weekly after dialysis dose dependently increased hematocrit, up to 10 percent at 3 weeks, and reduced the transfusion requirement (Eschbach et al., 1987).